8 news items
Bicycle Therapeutics to Present Pharmacokinetic and Safety Evaluation of Lead BTC® Molecules in Phase 1/2 Trials at the 2024 ASCO Annual Meeting
BCYC
23 May 24
registrational Phase 2/3 Duravelo-2 trial of BT8009, a Nectin-4 targeted Bicycle Toxin Conjugate, in patients with locally advanced or metastatic urothelial
e.l.f. Beauty Posts Upbeat Earnings, Joins Nvidia, LiveRamp Holdings, Borr Drilling And Other Big Stocks Moving Higher On Thursday
ACIU
AILE
BCYC
23 May 24
% to $157.32 after multiple analysts raised their price targets on the stock.
CI&T Inc
Bicycle Therapeutics Announces $555 Million Private Placement Equity Financing
BCYC
23 May 24
constrained with small molecule scaffolds to form two loops that stabilize their structural geometry. This constraint facilitates target binding with high
HC Wainwright & Co. Reiterates Buy on Bicycle Therapeutics, Maintains $55 Price Target
BCYC
3 May 24
HC Wainwright & Co. analyst Swayampakula Ramakanth reiterates Bicycle Therapeutics (NASDAQ:BCYC) with a Buy and maintains $55 price target.
Expert Ratings For Bicycle Therapeutics
BCYC
10 Apr 24
0
Analysts have set 12-month price targets for Bicycle Therapeutics, revealing an average target
yu37oh44h7770eoyje 6dtp55lkadh
BCYC
10 Apr 24
Needham analyst Ami Fadia reiterates Bicycle Therapeutics (NASDAQ:BCYC) with a Buy and maintains $43 price target.
0j5tjfpfprxf3t2rwx956om0hovy03
BCYC
2 Apr 24
constrained with small molecule scaffolds to form two loops that stabilize their structural geometry. This constraint facilitates target binding with high
t8lp8 pq2c2io5cnxxb
BCYC
5 Mar 24
Title: Tumor-targeted activation of CD137 using Bicycles: New insights into mechanism of action
- Prev
- 1
- Next